Iris Miedema

Iris Miedema

DRS.

20192023

Research activity per year

Network

Ellis Barbé

Person: Academic

Qizhi Hu

  • Cristal Therapeutics

External person

Ron H. J. Mathijssen

  • Erasmus Universiteit Rotterdam

External person

Rolf Grempler

  • Boehringer Ingelheim Pharma GmbH & Co. KG, 88397 Biberach an der Riss, Germany
  • Boehringer Ingelheim GmbH

External person

Sjoukje F. Oosting

  • University of Groningen, University Medical Center Groningen
  • University Medical Center Groningen
  • University of Groningen

External person

Carla M L van Herpen

  • Radboud University Medical Center
  • Radboud University Nijmegen

External person

Adrienne H. Brouwers

  • University Medical Center Groningen
  • University Medical Center Groningen, Centre for Revalidation (Beatrix Children's Hospital)
  • Afdeling Nucleaire Geneeskunde en Moleculaire beeldvorming
  • University of Groningen
  • Department of Obstetrics and Gynaecology

External person

Twan Lammers

  • Institute for Experimental Molecular Imaging, Aachen, Germany

External person

Sandra Heskamp

  • Department of Radiology and Nuclear Medicine, Nijmegen, Netherlands

External person

Cristianne Rijcken

  • Cristal Therapeutics

External person

J. H.M.S. Schellens

  • Netherlands Cancer Institute
  • Utrecht University
  • Antoni Van Leeuwenhoek Hospital
  • Slotervaart Hospital
  • Vrije Universiteit Amsterdam
  • Radboud University Nijmegen
  • Kirin Holdings Co., Ltd.
  • Netherlands C. Inst./A. van L. Hosp.
  • Erasmus Universiteit Rotterdam

External person

Wim E. Hennink

  • Department of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Faculty of Science, Utrecht University, Netherlands
  • Utrecht University

External person

Dick Pluim

  • NKI-AVL, Netherlands

External person

C. J.F. Rijcken

  • Utrecht University
  • Cristal Therapeutics

External person

Umut Aypar

  • Memorial Sloan Kettering Cancer Center

External person

Javier Garcia-Corbacho

  • Hospital Clinic de Barcelona
  • University of Barcelona

External person

Mabrouk Elgadi

  • Boehringer Ingelheim Pharmaceuticals

External person

Mariko Yabe

  • Memorial Sloan Kettering Cancer Center

External person

Hendrik-Tobias Arkenau

  • Sarah Cannon Research Institute SCRI UK

External person

M. Stella Ritorto

  • Memorial Sloan Kettering Cancer Center

External person

Alejandro Perez Pitarch

  • Boehringer Ingelheim Pharma GmbH & Co. KG Biberach

External person

Willeke Ros

  • NKI-AVL, Netherlands

External person

Ahmet Dogan

  • Memorial Sloan Kettering Cancer Center

External person

Neval Ozkaya

  • Memorial Sloan Kettering Cancer Center

External person

Sarah R. Verhoeff

  • Department of Medical Oncology, 6500 HB Nijmegen, Netherlands
  • Radboud University Nijmegen

External person

Filiz Sen

  • Memorial Sloan Kettering Cancer Center

External person

Erik H. Aarntzen

  • Department of Radiology and Nuclear Medicine, Nijmegen, Netherlands
  • Radboud University Nijmegen

External person

Dennis Vriens

  • Leiden University

External person

Alejandro Pitarch

  • Boehringer Ingelheim International GmbH

External person

Jos H. Beijnen

  • Utrecht University
  • Netherlands Cancer Institute
  • Slotervaart Hospital
  • Antoni Van Leeuwenhoek Hospital
  • Netherlands C. Inst./A. van L. Hosp.
  • ASTA Medica AG
  • Vrije Universiteit Amsterdam
  • Radboud University Nijmegen
  • Kirin Holdings Co., Ltd.
  • Sioterveert Hospital

External person

Alexander Peltzer

  • Boehringer Ingelheim Pharma GmbH & Co. KG Biberach

External person

Rob M.J. Liskamp

  • Utrecht University

External person

Sarah Verhoeff

  • Radboud Universiteit Nijmegen

External person

Rob Hanssen

  • Cristal Therapeutics

External person

Ellen Doeleman

  • Amsterdam UMC (location VUmc), Amsterdam, Netherlands

External person

Raphael Hesse

  • Boehringer Ingelheim Pharma GmbH & Co. KG Biberach

External person

Florence Atrafi

  • Erasmus Universiteit Rotterdam

External person